DE69740038D1 - - Google Patents

Info

Publication number
DE69740038D1
DE69740038D1 DE69740038T DE69740038T DE69740038D1 DE 69740038 D1 DE69740038 D1 DE 69740038D1 DE 69740038 T DE69740038 T DE 69740038T DE 69740038 T DE69740038 T DE 69740038T DE 69740038 D1 DE69740038 D1 DE 69740038D1
Authority
DE
Germany
Prior art keywords
adhesins
chimeric
heteromultimeric
erbb2
heteromultimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69740038T
Other languages
English (en)
Inventor
Vincent Danial Fizpatrick
Mark Sliwkowski
Richard L Vandlen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DE69740038D1 publication Critical patent/DE69740038D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
DE69740038T 1996-07-12 1997-07-08 Expired - Lifetime DE69740038D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2164096P 1996-07-12 1996-07-12
US79832697A 1997-02-10 1997-02-10
PCT/US1997/011825 WO1998002540A1 (en) 1996-07-12 1997-07-08 Chimeric heteromultimer adhesins

Publications (1)

Publication Number Publication Date
DE69740038D1 true DE69740038D1 (de) 2010-12-16

Family

ID=26694954

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69740038T Expired - Lifetime DE69740038D1 (de) 1996-07-12 1997-07-08

Country Status (13)

Country Link
US (3) US6696290B2 (de)
EP (2) EP0938556B1 (de)
JP (2) JP4274581B2 (de)
CN (1) CN1202247C (de)
AT (1) ATE486937T1 (de)
AU (1) AU722178B2 (de)
BR (1) BR9710357A (de)
CA (1) CA2258721C (de)
DE (1) DE69740038D1 (de)
DK (1) DK0912734T3 (de)
IL (1) IL127891A0 (de)
NZ (1) NZ333325A (de)
WO (1) WO1998002540A1 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2368823T3 (es) * 1998-01-26 2011-11-22 Genentech, Inc. Anticuerpos del receptor 4 de muerte (dr4) y usos de los mismos.
EP1745799B1 (de) 1998-03-04 2015-09-02 The Trustees of The University of Pennsylvania Zusammensetzungen und Verfahren zur Behandlung von Tumoren
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
ATE405651T1 (de) * 1998-03-17 2008-09-15 Genentech Inc Zu vegf und bmp1 homologe polypeptide
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
US20030022233A1 (en) * 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
AUPQ841800A0 (en) * 2000-06-28 2000-07-20 Biomolecular Research Institute Limited Truncated egf receptor
AU2001290524A1 (en) 2000-08-08 2002-02-18 Zymogenetics Inc. Soluble zcytor 11 cytokine receptors
US20020119148A1 (en) * 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7527794B2 (en) * 2001-07-31 2009-05-05 Wayne State University Hybrid proteins with neuregulin heparin-binding domain for targeting to heparan sulfate proteoglycans
EP1283053A1 (de) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitore der HER3 Aktivität
JP4660094B2 (ja) * 2002-03-26 2011-03-30 ゼンサン （シャンハイ） サイ−テク． リミテッド 新生物を治療するためのＥｒｂＢ３に基づく方法および組成物
WO2003099320A1 (en) 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
EP1572972A4 (de) * 2002-11-21 2007-11-21 Genentech Inc Therapie nichtmaligner krankheiten oder störungen mit anti-erbb2-antikörpern
SI1606409T1 (sl) * 2003-03-19 2011-01-31 Biogen Idec Inc Vezavni protein receptorja Nogo
ATE517914T1 (de) * 2004-03-08 2011-08-15 Zymogenetics Inc Dimere fusionsproteine und materialien und verfahren zu deren herstellung
ES2395094T3 (es) 2004-06-24 2013-02-08 Biogen Idec Ma Inc. Tratamiento de afecciones que implican la desmielinización
AU2005299809B2 (en) 2004-10-22 2010-12-02 Zymogenetics, Inc. Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
ATE517917T1 (de) 2005-06-03 2011-08-15 Ares Trading Sa Herstellung eines rekombinanten il-18-bindenden proteins
BRPI0613387A2 (pt) 2005-07-08 2011-01-11 Biogen Idec Inc anticorpo isolado ou fragmento de ligação de antìgeno deste e o seu uso, polinucleotìdeo isolado, composição, vetor, célula hospedeira, anticorpo anti-sp35 e método para a produção do mesmo, polipeptìdeo isolado, método in vitro para redução da inibição do crescimento axonal e método in vitro para inibição do crescimento do colapso do cone
DK1912675T3 (en) * 2005-07-25 2014-03-24 Emergent Product Dev Seattle B-cell reduction using specific and cd37-cd20-specific binding molecules
EP2543384A3 (de) * 2005-12-02 2013-04-10 Biogen Idec MA Inc. Behandlung von Zuständen mithilfe von Demyelinisation
CN101611150A (zh) * 2006-02-08 2009-12-23 利佳赛普特有限责任公司 二价ErbB配体结合分子及其制备和使用方法
JP2009525762A (ja) * 2006-02-08 2009-07-16 ターゲッティド・モレキュラー・ダイアグナスティクス・エルエルシー 二価性ＥｒｂＢリガンド結合分子ならびにその調製および使用のための方法
CN105802904B (zh) 2006-02-23 2021-04-20 维亚赛特公司 用于培养可分化细胞的组合物和方法
BRPI0713272A2 (pt) * 2006-06-12 2017-05-02 Receptor Biologix Inc produtos terapêuticos específicos ao receptor na superfície de pan-células
WO2007146968A2 (en) * 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
EP2035452B1 (de) 2006-06-22 2012-04-25 Novo Nordisk A/S Lösliche heterodimere rezeptoren und ihre verwendung
JP2009541275A (ja) * 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
PL2716301T3 (pl) 2007-02-16 2017-10-31 Merrimack Pharmaceuticals Inc Przeciwciała przeciw ERBB3 i ich zastosowania
US20090258005A1 (en) * 2007-05-29 2009-10-15 Trubion Pharmaceuticals Inc. Therapeutic compositions and methods
US20090304590A1 (en) * 2007-05-29 2009-12-10 Wyeth Therapeutic compositions and methods
WO2009048605A1 (en) * 2007-10-11 2009-04-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and trkb agonists
AU2008312580A1 (en) * 2007-10-16 2009-04-23 Symphogen A/S Compositions comprising optimized Her1 and Her3 multimers and methods of use thereof
JP5754046B2 (ja) * 2007-11-08 2015-07-22 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 脱髄を伴う状態の治療におけるｌｉｎｇｏ−４アンタゴニストの使用
NZ621443A (en) * 2008-04-11 2015-09-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
US8058406B2 (en) 2008-07-09 2011-11-15 Biogen Idec Ma Inc. Composition comprising antibodies to LINGO or fragments thereof
CN102224255A (zh) 2008-08-15 2011-10-19 梅里麦克制药股份有限公司 用于预测细胞对治疗剂的应答的方法和系统
US9198952B2 (en) 2008-09-22 2015-12-01 The Brigham And Women's Hospital, Inc. Compositions of and methods of using ligand dimers
DK2365987T3 (en) 2008-11-25 2015-01-12 Genentech Inc Isoform specific anti-HER4 antibodies
JP5926680B2 (ja) * 2009-07-28 2016-05-25 リガセプト・エルエルシー 広範囲のＥｒｂＢリガンド結合分子ならびにそれを調製および使用するための方法
SG183333A1 (en) 2010-02-18 2012-09-27 Genentech Inc Neuregulin antagonists and use thereof in treating cancer
DK2544680T3 (en) 2010-03-11 2015-04-27 Merrimack Pharmaceuticals Inc USE OF ErbB3 INHIBITORS IN TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER
EP2555788B1 (de) 2010-03-24 2017-10-11 Massachusetts Institute of Technology Neuregulin dimer für einen erbb/her rezeptor für die verwendung in reduzierung der kardiotoxizität
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
WO2012103114A2 (en) * 2011-01-24 2012-08-02 Jason Hill Therapeutic chimeric ligand binding proteins and methods for their use
EA030716B1 (ru) 2012-05-14 2018-09-28 Байоджен Ма Инк. Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны
WO2014051567A1 (en) * 2012-09-26 2014-04-03 Morehouse School Of Medicine Chimeric neuregulins and method of making and use thereof
JP6408492B2 (ja) 2013-02-18 2018-10-17 ヴェジェニクス プロプライエタリー リミテッドＶｅｇｅｎｉｃｓ Ｐｔｙ Ｌｉｍｉｔｅｄ リガンド結合分子およびその使用
BR112015032763A2 (pt) 2013-07-05 2017-11-07 H Lee Moffitt Cancer Ct & Res cd33 solúvel para tratar síndromes mielodisplásicas (mds)
EP3087394A2 (de) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarkerprofile zur vorhersage der ergebnisse einer krebstherapie mit erbb3-inhibitoren und/oder chemotherapien
AU2016205197B2 (en) 2015-01-08 2021-10-21 Biogen Ma Inc. LINGO-1 antagonists and uses for treatment of demyelinating disorders
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
KR20180117529A (ko) 2017-04-19 2018-10-29 주식회사 프로티나 단백질-단백질 상호작용 분석에 의한 약물 반응성 예측 방법
WO2019132517A1 (ko) * 2017-12-26 2019-07-04 주식회사 프로티나 세포 내 또는 세포 간 단백질-단백질 상호작용 분석 방법 및 장치
CN110669139A (zh) * 2019-09-18 2020-01-10 沣潮医药科技（上海）有限公司 二聚体免疫粘附素、药物组合物和用途
CN111018999B (zh) * 2019-12-05 2022-07-12 沣潮医药科技（上海）有限公司 二聚体免疫融合蛋白、药物组合物和用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
NZ226414A (en) 1987-10-02 1992-07-28 Genentech Inc Cd4 peptide adhesion variants and their preparation and use
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
ES2176174T3 (es) 1988-12-22 2002-12-01 Genentech Inc Procedimiento de preparacion de polipeptidos solubles en agua.
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
AU641673B2 (en) 1989-06-29 1993-09-30 Medarex, Inc. Bispecific reagents for aids therapy
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
EP0444961A1 (de) 1990-03-02 1991-09-04 Bristol-Myers Squibb Company Her3: Ein neues EGF-Rezeptor Homologes
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5254536A (en) * 1992-01-10 1993-10-19 The Du Pont Merck Pharmaceutical Company Therapeutic utility of plasminogen activator inhibitor-1 to control bleeding
US5635177A (en) * 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
AU668423B2 (en) 1992-08-17 1996-05-02 Genentech Inc. Bispecific immunoadhesins
CA2175892C (en) 1993-11-23 2000-03-07 Paul J. Godowski Kinase receptor activation assay
US5844092A (en) * 1994-03-18 1998-12-01 Genentech, Inc. Human TRK receptors and neurotrophic factor inhibitors
US5804396A (en) * 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides

Also Published As

Publication number Publication date
EP0912734B1 (de) 2010-11-03
US20040138417A1 (en) 2004-07-15
JP2008115187A (ja) 2008-05-22
CN1225129A (zh) 1999-08-04
US20070081994A1 (en) 2007-04-12
CA2258721A1 (en) 1998-01-22
IL127891A0 (en) 1999-10-28
JP4274581B2 (ja) 2009-06-10
BR9710357A (pt) 1999-08-17
EP0938556A1 (de) 1999-09-01
AU722178B2 (en) 2000-07-27
DK0912734T3 (da) 2011-02-07
US6696290B2 (en) 2004-02-24
US20030199020A1 (en) 2003-10-23
JP2000515372A (ja) 2000-11-21
ATE486937T1 (de) 2010-11-15
EP0912734A1 (de) 1999-05-06
NZ333325A (en) 2000-06-23
CA2258721C (en) 2014-09-09
US7659368B2 (en) 2010-02-09
WO1998002540A1 (en) 1998-01-22
CN1202247C (zh) 2005-05-18
AU3596297A (en) 1998-02-09
EP0938556B1 (de) 2005-03-09

Similar Documents

Publication Publication Date Title
DE69740038D1 (de)
IL127892A0 (en) Gamma-heregulin
NZ516258A (en) Tek antagonists
GB9022648D0 (en) Polypeptide and its use
BG104268A (en) Bitumen or asphalt for producing road surfacing, road surfacing and method for the preparation of bitumen or asphalt
TW200628490A (en) Novel anti-IGF-IR antibodies and uses thereof
MX9604316A (es) Anticuerpos agonistas de la proteina tirosina cinasa.
IL136728A0 (en) Novel g protein-coupled receptor
DE69616480T2 (de) Piperidinderivate als neurokininantagonisten
TR199902194T2 (xx) +p38 protein kinaz inhibit�rleri olarak ikameli azot ihtiva eden heterosikler.
MX9600666A (es) Proteinas de protocadherina y su uso.
HK1029595A1 (en) Cyclic antagonists of c5a receptors and g protein-coupled receptors
MX9605365A (es) Fracciones polipeptidicas solubles de la proteina lag-3; procedimiento de produccion; composicion terapeutica y anticuerpos ant-idiotipo.
IL126303A0 (en) Erbb3 antibodies
HU9700113D0 (en) Substituted pyrimidine compounds and their use
WO1999019488A8 (en) Novel human egf receptors and use thereof
NZ329807A (en) NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome
CA2171289A1 (en) Il8 inhibitors
AU2001245209A1 (en) Screening methods for bone morphogenetic mimetics
CA2147838A1 (en) The pct-65 serotonin receptor
HK1004411A1 (en) A novel haemopoietin receptor
IL187595A0 (en) Antitumor antibodies, proteins, and uses thereof
EP0858505A4 (de) Klonierung von pheromon rezeptoren aus vertebraten und deren verwendungen
AU2003288810A1 (en) Peptides that bind to the heparin binding domian of vegf and vegfr-2
ATE252152T1 (de) Pflanzenpromoter, microorganismen und pflanzenzellen mit einer expressionseinheit für ein gewünschtes protein, das besagten promoter enthält